文献速递乳腺癌放疗

临床淋巴结阴性患者中小叶癌成分预示升级为病理III期乳腺癌的可能性增加

A component of lobular carcinoma in clinically lymph node-negative patients predicts for an increased likelihood of upstaging to pathologic stage III breast cancer.
PubMed 文献 · Adv Radiat Oncol · 2018-02-26

本研究回顾性分析1997至2009年在本机构因前哨淋巴结阳性而接受乳房切除、前哨淋巴结活检及腋窝淋巴结清扫的345例临床T0-T2N0女性患者,比较含小叶癌成分者与不含者的病理升级情况。结果显示含小叶癌成分者阳性淋巴结数更多(2.79 vs 2.26,P=.009),升级至病理IIIA期及以上比例更高(30.9% vs 17.4%,P=.007)。

要点

  • 含小叶癌成分患者阳性淋巴结数2.79枚,不含者为2.26枚(P=.009)。
  • 含小叶癌成分患者升级至病理IIIA期及以上比例30.9%,不含者为17.4%(P=.007)。
  • 小叶癌成分与临床分期低估及术后放疗指征相关。

核心结论

  • 在本队列中,含小叶癌成分的患者更常被手术升级至病理IIIA期或更高,这是乳房切除术后放疗的经典指征。
  • 作者认为小叶癌的病变范围常比临床评估更广泛,对前哨淋巴结阳性后的小叶癌患者管理有重要影响。

研究设计与样本

  • 回顾性分析本机构1997年至2009年因前哨淋巴结阳性接受乳房切除、前哨淋巴结活检及完成性腋窝淋巴结清扫的345例既往未治疗、临床T0-T2N0女性患者。
  • 按手术病理是否存在小叶癌成分分组,比较阳性淋巴结总数、癌症分期、年龄、最终肿瘤大小及ER/PR/HER2状态。

主要发现

  • 345例中110例(32%)手术病理含小叶癌成分;295例(85.5%)为ER阳性,243例(70.4%)为PR阳性,56例(16.2%)为HER2阳性,28例(8.1%)为三阴性。
  • 含小叶癌成分患者阳性淋巴结数多于不含者(2.79 vs 2.26;P=.009)。
  • 含小叶癌成分患者升级至至少病理IIIA期的比例高于不含者(30.9% vs 17.4%;P=.007)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Physical examination and diagnostic imaging are often less precise in determining the extent of disease in invasive lobular carcinoma (ILC) relative to nonlobular histologies. Anecdotally, surgical axillary evaluation frequently reveals positive lymph nodes in clinically N0 patients with ILC; however, few studies quantify the likelihood of finding unsuspected disease at the time of surgery. In this study, we evaluate whether the presence of lobular histology increases the incidence of surgical upstaging to pathologic stage IIIA or greater in patients with a clinically node-negative axilla and positive sentinel lymph node (SLN) biopsy. METHODS AND MATERIALS: We examined patients from our institution between 1997 and 2009 treated specifically with mastectomy, SLN biopsy, and completion axillary lymph node dissection due to a positive SLN. For analysis, patients were grouped according to the presence of any lobular component on surgical pathology. The number of total positive lymph nodes, cancer stage, age, final tumor size, and ER/PR/HER2 status were assessed based on tumor histology. RESULTS: We evaluated 345 previously untreated women with clinical T0-T2 and N0 disease at the time of surgery. A total of 110 patients (32%) had a component of ILC on surgical pathology. In addition, 295 patients (85.5%) had ER + breast carcinoma, 243 (70.4%) had PR + disease, 56 (16.2%) were HER2 + , and 28 (8.1%) were triple negative. At the time of surgery, women with lobular disease were observed to have a greater number of positive lymph nodes (2.79 vs 2.26; P = .009) and were more frequently upstaged to at least pathologic stage IIIA compared with nonlobular patients (30.9% vs 17.4%; P = .007). CONCLUSIONS: In this cohort, patients with a component of lobular carcinoma were more often surgically upstaged to pathologic stage IIIA or higher, which is a classical indication for postmastectomy radiation therapy. Our findings suggest that ILC is often more extensive than it appears clinically and has significant implications for management of patients with lobular carcinoma after the discovery of a positive SLN.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Van Wyhe RD, Caudle AS, Shaitelman SF, et al. A component of lobular carcinoma in clinically lymph node-negative patients predicts for an increased likelihood of upstaging to pathologic stage III breast cancer. Adv Radiat Oncol. 2018. PMID: 30197937. doi:10.1016/j.adro.2018.02.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。